Atopic Dermatitis
Conditions
Interventions
Experimental group:Basic treatment+topical oxysophocarpine cream
Control group:Basic treatment+topical desonide cream
Sponsors
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Meets the diagnostic criteria for atopic dermatitis according to the Williams classification; disease severity is mild to moderate (IGA: 2-3 points or EASI: 0-21 points); 2. Aged >=18 years and <=70 years, regardless of gender; 3. Understands and agrees to participate in the study and has signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Presence of other active skin diseases that may interfere with the evaluation of the condition, such as contact dermatitis; 2. Systemic treatment with biological agents or immunosuppressants within the past month or currently receiving such treatments; 3. Use of topical medications within the past 14 days, including calcineurin inhibitors (tacrolimus or pimecrolimus), corticosteroids, PDE-4 inhibitors (crisaborole), JAK inhibitors (ruxolitinib), or topical antihistamines; 4. Presence of severe, uncontrolled local or systemic acute or chronic infections; 5. History of severe systemic diseases (e.g., cardiovascular, respiratory, digestive, neurological, endocrine, or urogenital diseases); 6. History of malignant tumors or primary or secondary immunodeficiency, or hypersensitivity conditions; 7. Undergoing or scheduled for major surgery within 8 weeks prior to the study or during the study period; 8. Pregnant or breastfeeding women, or women planning to become pregnant in the near future; 9. History of alcohol abuse, drug addiction, or substance misuse; 10. History of severe psychiatric disorders or a family history of such conditions; 11. Participation in another clinical trial within the past month or currently enrolled in another trial; 12. Poor compliance with study requirements or any other reasons deemed unsuitable for participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eczema area and severity index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Investigator's global assessment;Dermatology life quality index;Visual analogue scale;Determination of recurrence; | — |
Countries
China
Contacts
Public ContactMi Zhou/Hao Wang
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Outcome results
None listed